Filing Details

Accession Number:
0001415889-25-009074
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-03-26 20:06:10
Reporting Period:
2025-03-24
Filing Date:
2025-03-26
Accepted Time:
2025-03-26 20:06:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1899977 C. Mark Schneyer C/O Acadia Pharmaceuticals Inc.
12830 El Camino Real, Suite 400
San Diego CA 92130
Evp, Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2025-03-25 6,178 $0.00 60,060 No 4 M Direct
Common Stock Disposition 2025-03-26 3,171 $17.05 56,889 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2025-03-24 110,761 $0.00 110,761 $17.23
Common Stock Restricted Stock Units Acquisiton 2025-03-24 32,552 $0.00 32,552 $0.00
Common Stock Restricted Stock Units Disposition 2025-03-25 6,178 $0.00 6,178 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
110,761 2035-03-23 No 4 A Direct
32,552 No 4 A Direct
18,536 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  2. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
  3. 25% of the shares subject to the Stock Option will vest and become exercisable on March 24, 2026. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
  4. The restricted stock units vest in four equal annual installments beginning March 24, 2026.
  5. The restricted stock units vest in four equal annual installments beginning March 25, 2025.